Decreased Survival and Lung Function in Progressive Pulmonary Fibrosis

Decreased Survival and Lung Function in Progressive Pulmonary Fibrosis

<i>Background and Objectives:</i> Progressive pulmonary fibrosis (PPF) is a recently described term reserved for patients with fibrotic ILD other than idiopathic pulmonary fibrosis (IPF) with fast clinical deterioration. Here, survival and prognostic biomarkers at the time of diagnosis f...

Full description

Bibliographic Details
Main Authors:	Mark G. J. P. Platenburg, Joanne J. van der Vis, Jan C. Grutters, Coline H. M. van Moorsel
Format:	Article
Language:	English
Published:	MDPI AG 2023-02-01
Series:	Medicina
Subjects:	PPF progressive pulmonary fibrosis survival ILD FVC DLCOc
Online Access:	https://www.mdpi.com/1648-9144/59/2/296

Similar Items

Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases
by: Stefan Cristian Stanel, et al.
Published: (2023-02-01)

Risk factors for progression of pulmonary fibrosis: a single-centered, retrospective study
by: Jia-Jia Fan, et al.
Published: (2024-02-01)

An observational cohort study of interstitial lung abnormalities (ILAs) in a large Japanese health screening population (Kumamoto ILA study in Japan: KILA-J)
by: Kazuya Ichikado, et al.
Published: (2023-06-01)

Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis: Part A
by: Ivo A. Wiertz, et al.
Published: (2020-06-01)

Optimizing Screening for Early Disease Detection in Familial Pulmonary Fibrosis (FLORIS): A Prospective Cohort Study Design
by: Martijn T. K. Maus, et al.
Published: (2023-01-01)

Editorial: Pulmonary fibrosis: One manifestation, various diseases
by: Barbara Ruaro, et al.
Published: (2022-10-01)

Genetic Variant Overlap Analysis Identifies Established and Putative Genes Involved in Pulmonary Fibrosis
by: Karlijn Groen, et al.
Published: (2023-02-01)

Towards Treatable Traits for Pulmonary Fibrosis
by: Thijs W. Hoffman, et al.
Published: (2022-08-01)

Bridges of Pulmonology 2023 proceedings: Highlights in the field of interstitial lung diseases
by: Vasilina Sotiropoulou, et al.
Published: (2024-03-01)

The impact of respiratory reactance in oscillometry on survival in patients with idiopathic pulmonary fibrosis
by: Tatsuru Ishikawa, et al.
Published: (2024-01-01)

New Insights via RNA Profiling of Formalin-Fixed Paraffin-Embedded Lung Tissue of Pulmonary Fibrosis Patients
by: Dymph Klay, et al.
Published: (2023-11-01)

Pulmonary Fibrosis and Progressive Pulmonary Fibrosis in a Prospective Registry of Interstitial Lung Diseases in Eastern Siberia
by: Maria S. Nashatyreva, et al.
Published: (2023-01-01)

Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis
by: M. C. Schimmelpennink, et al.
Published: (2022-06-01)

Lung Ultrasound in the Screening of Pulmonary Interstitial Involvement Secondary to Systemic Connective Tissue Disease: A Prospective Pilot Study Involving 180 Patients
by: Natalia Buda, et al.
Published: (2021-09-01)

Heritability of pulmonary function estimated from pedigree and whole-genome markers.
by: Yann C. Klimentidis, et al.
Published: (2013-09-01)

Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg)
by: Ekaterina Krauss, et al.
Published: (2020-11-01)

Reticulation pattern without honeycombing on high-resolution CT is associated with the risk of disease progression in interstitial lung diseases
by: Minna Mononen, et al.
Published: (2022-08-01)

Evaluation of Regional Pulmonary Ventilation in Spontaneously Breathing Patients with Idiopathic Pulmonary Fibrosis (IPF) Employing Electrical Impedance Tomography (EIT): A Pilot Study from the European IPF Registry (eurIPFreg)
by: Ekaterina Krauss, et al.
Published: (2021-01-01)

Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung Disease
by: Lutz B. Jehn, et al.
Published: (2023-02-01)

Transbronchial lung cryobiopsy and pulmonary fibrosis: A never-ending story?
by: Barbara Ruaro, et al.
Published: (2023-04-01)

Progressive pulmonary fibrosis in myositis-specific antibody-positive interstitial pneumonia: a retrospective cohort study
by: Huijuan Wang, et al.
Published: (2024-01-01)

Serum Biomarkers in Differential Diagnosis of Idiopathic Pulmonary Fibrosis and Connective Tissue Disease-Associated Interstitial Lung Disease
by: Eva Cabrera Cesar, et al.
Published: (2021-07-01)

CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies
by: Elisabetta Zanatta, et al.
Published: (2023-05-01)

Real-world practice of idiopathic pulmonary fibrosis: Results from a 2000–2016 cohort
by: Wang Ying-Tso, et al.
Published: (2023-11-01)

Effects of Pirfenidone on Idiopathic Pulmonary Fibrosis Progression and Safety: Results of Multicenter Prospective Observational Study
by: Sergey Avdeev, et al.
Published: (2023-02-01)

Progressive Pulmonary Fibrosis: Where Are We Now?
by: Hyung Koo Kang, et al.
Published: (2024-04-01)

Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis—Part B
by: Canay Caliskan, et al.
Published: (2020-06-01)

Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study
by: Kyung-In Joung, et al.
Published: (2023-03-01)

Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients?
by: U. Costabel
Published: (2011-09-01)

No effect of danazol treatment in patients with advanced idiopathic pulmonary fibrosis
by: Thijs W. Hoffman, et al.
Published: (2023-09-01)

Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies
by: Hehua Guo, et al.
Published: (2023-08-01)

Efficacy of Pirfenidone According to Dose in Patients with Idiopathic Pulmonary Fibrosis: A Prospective, Observational, Single-Center Cohort Study
by: Ho Young Lee, et al.
Published: (2023-10-01)

What is new in the treatment of interstitial lung diseases
by: Vasilina Sotiropoulou, et al.
Published: (2023-06-01)

Targeting Progression in Pulmonary Fibrosis: An Overview of Underlying Mechanisms, Molecular Biomarkers, and Therapeutic Intervention
by: Vito D’Agnano, et al.
Published: (2024-02-01)

Prognostic Biomarkers in Idiopathic Pulmonary Fibrosis: a Recent Review
by: XU Lili, HONG Yunzhe, LI Zhihui, YU Ningxia, DI Jiaqi, YANG Shuguang, LIN Qingqing, YU Xueqing
Published: (2023-01-01)

Assessment of survival in patients with idiopathic pulmonary fibrosis using quantitative HRCT indexes
by: Sebastiano Emanuele Torrisi, et al.
Published: (2018-12-01)

Diagnosing interstitial lung disease by multidisciplinary discussion: A review
by: Laura M. Glenn, et al.
Published: (2022-09-01)

Pulmonary Hypertension Associated Genetic Variants in Sarcoidosis Associated Pulmonary Hypertension
by: Karlijn Groen, et al.
Published: (2022-10-01)

A Cross-Sectional Survey of Pulmonologists Working at Non-ILD Centers in the United States
by: Biehl R, et al.
Published: (2023-07-01)

Assessment of progression of pulmonary fibrosis based on metabonomics and analysis of intestinal microbiota
by: Jia-qi Liu, et al.
Published: (2024-12-01)